MRCLS had clinical responses with lete-celResults include six complete responses (6/64); twenty-one partial responses ...

Greetings, and welcome to the Moleculin Biotech Quarterly Update Conference Call and Webcast. At this time, all participants are in listen only mode. [Operator Instructions] A question-and-answer ...

Reducing the risk of metastatic relapse in patients with resectable soft tissue sarcomas is crucial for improving outcomes, because metastasis is the primary cause of mortality in this population.

Reported positive YTD 2024 Adjusted EBITDA of $1.4 million Company expects Q4 2024 Net Revenue in the range of $37 million - $43 million ZYNRELEF® (bupivacaine ...

Aileen Lamb hopes the approval of a new cancer treatment drug will give patients 'hope', after she was given the all clear ...

Aileen Lamb, from Edinburgh who had acute myeloid leukaemia said the approval of the new drug gives sufferers hope.

Health experts want blood- and breast-cancer patients prescribed exercise to mitigate heart damage during treatment.

For patients with operative triple-negative breast cancer, a multigene signature can help tailor adjuvant chemotherapy.

On track to start dosing in pivotal, adaptive Phase 3 clinical trial (the "MIRACLE" trial) designed for possible accelerated approval of Annamycin in combination with cytarabine for the treatment of R ...

Drug-eluting beads (DEB) are new spherical and deformable polyvinyl alcohol and hydrophilic ionic monomer beads that can be loaded with anthracycline drugs, such as doxorubicin. [20] The loaded ...